~~<i id='65BDC04553'><strike id='65BDC04553'><tt id='65BDC04553'><pre id='65BDC04553'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

hotspot

author：focus 2025-10-01 17:20:17 - browse：16

Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. But some in the industry worry about the unintended consequences of overreliance.

Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.

When the American Society of Health-System Pharmacists surveyed its members this past summer, 59% said they increased purchases from compounders because of drug shortages.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Readout Newsletter: New research from Sanofi, Regeneron, etc.

focus

hotspot

focus

hotspot

entertainment

AndrewHarnik/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnews

WSS

Medical device lobby: We're tired of waiting on Medicare coverage

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

RSV vaccines may be linked to small increased risk of developing GBS

Physician subsidies by hospitals soar in wake of No Surprises Act

First Opinion Podcast: How to protect health care in times of war

leisure time

hotspot

focus

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Hollywood unions extend contract negotiations for actors

An inside look at PIPEs, biotech's buzzy new financing tool

How one medical school became remarkably diverse

Readout Newsletter: New research from Sanofi, Regeneron, etc.

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: XBI biotech index, Akero Therapeutics

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The FDA weighs the risks of candy

hotspot

Telehealth options flood the market as retailers push virtual care

Diversifying clinical trials isn't enough to close racial gaps: study

Readout Newsletter: New research from Sanofi, Regeneron, etc.

RaDonda Vaught to speak at CommonSpirit event on patient safety

Traditional Chinese medicine benefits explored in new JAMA study

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

focus

hotspot

entertainment

entertainment